免責聲明: 本站彙整 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公開資料,僅供一般參考,不構成醫療建議、診斷、治療建議或投資建議。

FDA 510(k)

埃佛里安+系統

K 號:K213863 · 2023-02-23

決定日期2023-02-23
產品代碼MSX
諮詢委員會履歷
決定相當於

器材摘要

Everion+ System is the device name listed in this FDA 510(k) record. The listed applicant is Biofourmis Singapore Pte., Ltd.. It received FDA 510(k) clearance on 2023-02-23 under 510(k) number K213863. The device is classified under product code MSX. It was reviewed by the CV advisory panel. FDA Decision: Substantially Equivalent.

常見問題

What is the Everion+ System?

Everion+ System is a medical device that received FDA 510(k) clearance on 2023-02-23. The listed applicant is Biofourmis Singapore Pte., Ltd.. The 510(k) number is K213863.

When did Everion+ System receive FDA 510(k) clearance?

Everion+ System received FDA 510(k) clearance on 2023-02-23, under 510(k) number K213863.

Who is the listed applicant for Everion+ System?

The FDA 510(k) record lists Biofourmis Singapore Pte., Ltd. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Everion+ System?

The FDA product code for Everion+ System is MSX.

相關臨床試驗

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

其他以 Biofourmis Singapore Pte., Ltd. 為申請人之記錄

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

相關器械(代碼:MSX)

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

官方來源

在 FDA 資料庫中查看 →

資料來源為 FDA Open API。如需最新且權威的資訊,請始終參閱官方記錄。

↑